Biosimilars

Pharmalot By Ed Silverman

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

Pharmalot By Ed Silverman

Large employers could have saved money if more biosimilars had been prescribed

First Opinion By Carol Lynch

Biosimilars could disappear if the Supreme Court overturns the ACA

First Opinion By Sean McGowan

Five years on, biosimilars need support from all health care players

Pharmalot By Ed Silverman

FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake

Pharmalot By Ed Silverman

Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

Pharmalot By Ed Silverman

More hospital drug spending is going toward cancer immunotherapies

Pharmalot By Ed Silverman

Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast

First Opinion By Juliana Reed

Some bipartisan support for biosimilars is good. More would be better

Pharmalot By Ed Silverman

Pharmalittle: Judge summons opioid CEOs before trial starts; Republicans fail to change Pelosi drug pricing bill

First Opinion By Jonathan Kimball

Trade agreement drug monopoly is obsolete given faster, better drug discovery

Pharmalot By Ed Silverman

Pharmalittle: New records show drug makers’ opioid push; Senate bill would cap Medicare drug price hikes

Pharmalot By Ed Silverman

Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin

Pharmalot By Ed Silverman

Pharmalittle: Democrats eye negotiating for all drug plans; feds want part of Oklahoma settlement with Purdue

Pharmalot By Ed Silverman

FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed

Pharmalot By Ed Silverman

AbbVie settles key patent litigation over Humira, preserving ‘monopoly prices’ in the U.S.

Pharmalot By Ed Silverman

AbbVie is eager for its new psoriasis drug to be a hit, but analysts offer caveats

Pharmalot By Ed Silverman

Pharmalittle: U.K. adviser complains pharma ignores antibiotics; FDA to revamp manufacturing rules

First Opinion By Carlos Sattler and Sheila Frame

Biosimilar approval and adoption in the U.S. needs to be expedited

Pharmalot By Ed Silverman

What’s in a name? FDA changes course for biosimilar names and upsets generic makers

Pharmalot By Ed Silverman

AbbVie must fork over Humira documents after judge slams a ‘nonsense’ argument

Pharmalot By Ed Silverman

Pharmalittle: Senate committee ‘reinvites’ big drug makers to testify; can pharma use AI to solidify patents?

First Opinion By Richard Markus

Biosimilars and interchangeability: The FDA’s science-based standards will ensure safety

Pharmalot By Ed Silverman

Pharmalittle: Glaxo looks for a new chairman; FDA ponders whom to furlough as shutdown drags on

Pharmalot By Ed Silverman

Most Read

Merck to spin off new $6.5 billion firm focused on women’s health, older drugs

From bench to bedside, biologics require excellence at every stage

Combatting misinformation on biosimilars and preparing the market for them can save the U.S. billions

Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

U.S. biologics and biosimilars need distinguishable names

Watch: What is a biosimilar, exactly?

Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation

Booker-Sanders-Harris drug affordability bureau could be brilliant

All Coverage

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

Large employers could have saved money if more biosimilars had been prescribed

Biosimilars could disappear if the Supreme Court overturns the ACA

Five years on, biosimilars need support from all health care players

FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake

Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

More hospital drug spending is going toward cancer immunotherapies

Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast

Some bipartisan support for biosimilars is good. More would be better

Pharmalittle: Judge summons opioid CEOs before trial starts; Republicans fail to change Pelosi drug pricing bill

Trade agreement drug monopoly is obsolete given faster, better drug discovery

Pharmalittle: New records show drug makers’ opioid push; Senate bill would cap Medicare drug price hikes

Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin

Pharmalittle: Democrats eye negotiating for all drug plans; feds want part of Oklahoma settlement with Purdue

FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed

AbbVie settles key patent litigation over Humira, preserving ‘monopoly prices’ in the U.S.

AbbVie is eager for its new psoriasis drug to be a hit, but analysts offer caveats

Pharmalittle: U.K. adviser complains pharma ignores antibiotics; FDA to revamp manufacturing rules

Biosimilar approval and adoption in the U.S. needs to be expedited

What’s in a name? FDA changes course for biosimilar names and upsets generic makers

AbbVie must fork over Humira documents after judge slams a ‘nonsense’ argument

Pharmalittle: Senate committee ‘reinvites’ big drug makers to testify; can pharma use AI to solidify patents?

Biosimilars and interchangeability: The FDA’s science-based standards will ensure safety

Pharmalittle: Glaxo looks for a new chairman; FDA ponders whom to furlough as shutdown drags on

Pharmalittle: A new year brings rising drug prices; Democratic presidential contenders target drug prices